Hefei Lifeon Pharmaceutical Co Ltd Net Asset Quality Index
Hefei Lifeon Pharmaceutical Co Ltd net asset quality index. Hefei Lifeon Pharmaceutical Co Ltd (003020) has a Net Asset Quality Index of 75.7% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.61 Billion minus total liabilities of CN¥634.92 Million yields net assets of CN¥1.98 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See Hefei Lifeon Pharmaceutical Co Ltd net assets for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Hefei Lifeon Pharmaceutical Co Ltd (2012–2025)
Net asset quality index of Hefei Lifeon Pharmaceutical Co Ltd from 2012 to 2025. This chart shows how Hefei Lifeon Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 13 annual periods from 2012 to 2025. As of June 2026, the index stands at 75.7%, representing net assets of CN¥1.98 Billion against total assets of CN¥2.61 Billion CNY. Check 003020 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Hefei Lifeon Pharmaceutical Co Ltd Net Asset Quality Index by Year (2012–2025)
Hefei Lifeon Pharmaceutical Co Ltd net asset quality index by year from 2012 to 2025. The table below presents the year-by-year Net Asset Quality Index for Hefei Lifeon Pharmaceutical Co Ltd from 2012 to 2025, covering 13 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Hefei Lifeon Pharmaceutical Co Ltd (003020) market capitalisation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 75.5% | CN¥1.95 Billion | CN¥2.59 Billion | CN¥634.19 Million | ▲ +1.5 pp |
| 2024 | 74.0% | CN¥1.91 Billion | CN¥2.59 Billion | CN¥673.38 Million | ▼ -1.5 pp |
| 2023 | 75.4% | CN¥1.87 Billion | CN¥2.48 Billion | CN¥610.18 Million | ▲ +5.7 pp |
| 2022 | 69.8% | CN¥1.48 Billion | CN¥2.12 Billion | CN¥641.53 Million | ▼ -8.1 pp |
| 2021 | 77.9% | CN¥1.30 Billion | CN¥1.67 Billion | CN¥370.53 Million | ▲ +1.4 pp |
| 2020 | 76.4% | CN¥1.17 Billion | CN¥1.54 Billion | CN¥362.03 Million | ▲ +10.1 pp |
| 2019 | 66.3% | CN¥590.00 Million | CN¥889.81 Million | CN¥299.82 Million | ▲ +0.7 pp |
| 2018 | 65.6% | CN¥505.70 Million | CN¥771.01 Million | CN¥265.31 Million | ▲ +6.6 pp |
| 2017 | 59.0% | CN¥361.71 Million | CN¥612.85 Million | CN¥251.14 Million | ▲ +4.6 pp |
| 2016 | 54.4% | CN¥298.09 Million | CN¥547.80 Million | CN¥249.71 Million | ▲ +9.1 pp |
| 2014 | 45.3% | CN¥215.53 Million | CN¥475.64 Million | CN¥260.11 Million | ▲ +5.7 pp |
| 2013 | 39.6% | CN¥176.88 Million | CN¥446.22 Million | CN¥269.34 Million | ▲ +0.1 pp |
| 2012 | 39.6% | CN¥141.96 Million | CN¥358.64 Million | CN¥216.67 Million | — |